PIK3CA and malignant colon neoplasm: Compared to the HCT116 and DLD1 PIK3CA-mutant cells, the cell viability of the WT cells was greatly reduced upon treatment with AZD6244 or RDEA119, indicating that PIK3CA mutation enhanced drug resistance of colon cancer cells (Fig. 8D).